Display options
Cite
Calistri L, Cordopatri C, Nardi C, et al. Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. Mol Clin Oncol. 2017;6(3):389-396doi: 10.3892/mco.2017.1132.
Calistri, L., Cordopatri, C., Nardi, C., Gianni, E., Marra, F., & Colagrande, S. (2017). Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. Molecular and clinical oncology, 6(3), 389-396. https://doi.org/10.3892/mco.2017.1132
Calistri, Linda, et al. "Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis." Molecular and clinical oncology vol. 6,3 (2017): 389-396. doi: https://doi.org/10.3892/mco.2017.1132
Calistri L, Cordopatri C, Nardi C, Gianni E, Marra F, Colagrande S. Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. Mol Clin Oncol. 2017 Mar;6(3):389-396. doi: 10.3892/mco.2017.1132. Epub 2017 Jan 16. PMID: 28451419; PMCID: PMC5403270.
Copy Download .nbib Format: NLM
Share it on

Mol Clin Oncol. 2017 Mar;6(3):389-396. doi: 10.3892/mco.2017.1132. Epub 2017 Jan 16.

Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.

Molecular and clinical oncology

Linda Calistri, Cesare Cordopatri, Cosimo Nardi, Elena Gianni, Fabio Marra, Stefano Colagrande

Affiliations

  1. Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. 2, University of Florence-Azienda Ospedaliero-Universitaria Careggi, I-50134 Florence, Italy.
  2. Department of Experimental and Clinical Medicine, University of Florence, I-50134 Florence, Italy.

PMID: 28451419 PMCID: PMC5403270 DOI: 10.3892/mco.2017.1132

Abstract

Hepatocellular carcinoma (HCC) is the principal primary liver tumor, representing the third largest cause of cancer-associated death worldwide. The actual reference standard systemic treatment for advanced HCC is represented by sorafenib, a multi-targeted orally active small-molecule tyrosine kinase inhibitor. Sorafenib has exhibited a good general safety profile in multiple clinical trials. However, adverse drug-associated events are common, occasionally severe, and special attention should be paid to cardiovascular adverse events, particularly in patients with risk factors or known heart disease. In the present study, the case of a patient with no known cardiovascular risk factors affected by highly enhancing advanced HCC in cirrhotic liver, who died during successful sorafenib monotherapy, is reported.

Keywords: case report; hepatocellular carcinoma; sorafenib; sudden cardiac death; tyrosine kinase inhibitor; vascular endothelial growth factor

References

  1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  2. Cancer Res. 2004 Oct 1;64(19):7099-109 - PubMed
  3. Lancet. 2012 Mar 31;379(9822):1245-55 - PubMed
  4. Nat Rev Clin Oncol. 2010 Aug;7(8):476-80 - PubMed
  5. Toxicol Sci. 2015 Feb;143(2):374-84 - PubMed
  6. Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1106-10 - PubMed
  7. J Magn Reson Imaging. 1996 Mar-Apr;6(2):311-21 - PubMed
  8. Oncologist. 2008 Feb;13(2):120-5 - PubMed
  9. Am J Gastroenterol. 2009 Jul;104(7):1852-4 - PubMed
  10. Oncol Lett. 2014 Jan;7(1):50-52 - PubMed
  11. Semin Liver Dis. 2010 Feb;30(1):52-60 - PubMed
  12. Target Oncol. 2010 Mar;5(1):59-63 - PubMed
  13. N Engl J Med. 2007 Jan 11;356(2):125-34 - PubMed
  14. Hepatology. 2012 Dec;56(6):2416-9 - PubMed
  15. J Magn Reson Imaging. 2007 Apr;25(4):755-65 - PubMed
  16. Radiol Med. 2014 Aug;119(8):625-33 - PubMed
  17. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  18. Liver Int. 2011 May;31(5):740-3 - PubMed
  19. Cancer. 2010 Oct 1;116(19):4590-6 - PubMed
  20. Intern Med. 2013;52(14):1589-92 - PubMed
  21. Oncotarget. 2015 Jun 30;6(18):16449-60 - PubMed
  22. Hepatol Res. 2014 Dec;44(13):1268-76 - PubMed
  23. Am J Clin Oncol. 1982 Dec;5(6):649-55 - PubMed
  24. World J Gastroenterol. 2011 May 21;17 (19):2450-3 - PubMed
  25. Crit Rev Oncol Hematol. 2011 Dec;80(3):369-79 - PubMed
  26. World J Gastroenterol. 2014 Oct 21;20(39):14505-9 - PubMed
  27. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  28. J Clin Oncol. 2009 Jul 10;27(20):3312-8 - PubMed
  29. J Magn Reson Imaging. 2009 Nov;30(5):1012-20 - PubMed
  30. Herz. 2011 Jun;36(4):348-51 - PubMed
  31. Br J Surg. 1973 Aug;60(8):646-9 - PubMed
  32. J Exp Clin Cancer Res. 2006 Sep;25(3):403-9 - PubMed
  33. Cancer Treat Rev. 2012 Nov;38(7):919-25 - PubMed
  34. Cardiovasc Toxicol. 2010 Mar;10(1):1-8 - PubMed
  35. BMC Cancer. 2012 Jun 11;12 :231 - PubMed
  36. Gastroenterology. 2011 May;140(5):1410-26 - PubMed
  37. BMC Gastroenterol. 2011 Jan 17;11:4 - PubMed
  38. J Clin Invest. 2002 Apr;109(7):849-55 - PubMed
  39. J Hematol Oncol. 2008 Oct 17;1:18 - PubMed
  40. Br J Cancer. 2007 Jun 18;96(12 ):1788-95 - PubMed
  41. J Clin Oncol. 2008 Nov 10;26(32):5204-12 - PubMed
  42. Oncol Lett. 2013 Jan;5(1):381-385 - PubMed
  43. J Clin Oncol. 2011 Apr 20;29(12):e330-2 - PubMed
  44. AJR Am J Roentgenol. 2004 Dec;183(6):1619-28 - PubMed
  45. Cancer Res. 2006 Dec 15;66(24):11851-8 - PubMed
  46. J Cardiol. 2009 Dec;54(3):512-5 - PubMed
  47. Cancer Chemother Pharmacol. 2011 Apr;67(4):751-64 - PubMed
  48. J Hepatol. 2013 Jan;58(1):169-77 - PubMed
  49. Oncologist. 2009 Jan;14(1):95-100 - PubMed
  50. Nat Rev Cancer. 2007 May;7(5):332-44 - PubMed
  51. Clin Cancer Res. 2012 Apr 15;18(8):2290-300 - PubMed

Publication Types